CRP
CERES GLOBAL AG CORP
stock TSE

Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis. Key highlights include:
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
Pain Reduction: Average pain intensity decreased significantly from 5.8 to 2.1 on an 11-point scale after eight weeks.
C-Reactive Protein (CRP) Levels: Marked reduction in inflammation, comparable to Kiniksa’s rilonacept from the Phase III RHAPSODY trial.

Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis. Key highlights include:
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
Pain Reduction: Average pain intensity decreased significantly from 5.8 to 2.1 on an 11-point scale after eight weeks.
C-Reactive Protein (CRP) Levels: Marked reduction in inflammation, comparable to Kiniksa’s rilonacept from the Phase III RHAPSODY trial.